title: [Imaging of pediatric brain tumors using somatostatin analogue 111Ih-DTPA-D-Phe1-octreotide].
abstract: Malignant solid tumors and leukemias are the second most common causes of death in childhood. The most frequent pediatric solid tumors are brain tumors. Brain tumors, especially medulloblastoma should be treated by surgery, irradiation and chemotherapy. However, chemotherapy has only moderate effect. Pediatric brain tumors, especially medulloblastomas, express somatostatin receptors. The aim of this study was the investigation of the expression of somatostatin receptors in pediatric brain tumors for diagnostic and therapeutic purpose. Fifty-six scintigraphic imagings (111In-DTPA-D-Phe1-octreotide) made in 45 children treated with brain tumor at the Unit of Oncology of the 2nd Department of Pediatrics, Semmelweis University. The diagnosis was medulloblastoma in 21 cases (46.7%). MRI scans have been performed parallel with the Octreoscan images. Octreoscan images were positive in 27 of 56 (48.2%) cases. The 27 positive Octreoscan images consisted of 16 medulloblastomas, 4 ependymomas, 4 astrocytomas and 3 glioblastomas. In 37 (66.1%) cases the results of Octreoscans were the same as those of the MRI scans. However, in 19 scans (33.9%) the outcome was different. Octreoscan imaging is not suitable for differential diagnosis in pediatric brain tumors, including medulloblastomas. Isotopes specifically binding to the somatostatin receptors (111In-DTPA-D-Phe1-octreotide) can be applied in medulloblastomas for diagnosis and follow-up treatment. In Octreoscan-positive tumors the Octreoscan images establish the opportunity to somatostatin analogue and/or specifically targeted radiation therapies.
authors.affiliation: Transzplantációs és Sebészeti Klinika, Semmelweis Egyetem AOK, Budapest, Hungary. dabasi@trans.sote.hu
authors.forename: Gabriella
authors.initials: G
authors.lastname: Dabasi
authors.forename: Péter
authors.initials: P
authors.lastname: Hauser
authors.forename: Gabriella P
authors.initials: GP
authors.lastname: Kertész
authors.forename: György
authors.initials: G
authors.lastname: Balázs
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Karádi
authors.forename: Tamás
authors.initials: T
authors.lastname: Constantin
authors.forename: László
authors.initials: L
authors.lastname: Bognár
authors.forename: Almos
authors.initials: A
authors.lastname: Klekner
authors.forename: Dezsô
authors.initials: D
authors.lastname: Schuler
authors.forename: Miklós
authors.initials: M
authors.lastname: Garami
mesh_terms: D000293:Adolescent; D001254:Astrocytoma / Q000000981:diagnostic imaging; D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D002648:Child; D002675:Child, Preschool; D004806:Ependymoma / Q000000981:diagnostic imaging; D005260:Female; D005909:Glioblastoma / Q000000981:diagnostic imaging; D006801:Humans; D007205:Indium Radioisotopes; D007223:Infant; D007231:Infant, Newborn; D008279:Magnetic Resonance Imaging; D008297:Male; D008527:Medulloblastoma / Q000000981:diagnostic imaging; D015282:Octreotide / Q000031:analogs & derivatives*; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin / Q000378:metabolism*
chemical_list: D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide